Single-dose Janssen COVID vaccine 66% effective in phase 3 trial

Results from a phase 3 clinical trial have shown the Janssen COVID-19 vaccine, which is part of the UK’s vaccine portfolio, to be 66% effective overall at preventing moderate to severe illness.